Terray Therapeutics Valuation, Funding & Investors

Alpha Biopharma is a Shanghai-headquartered clinical-stage biopharmaceutical company advancing innovative drugs in oncology, immunology, and metabolic diseases. The firm conducts global trials in partnership with CROs and in-licenses assets from international developers, maintaining R&D facilities in China and the US.

Novartis India Ltd is an Indian-based pharmaceutical company. The company is engaged in the trading of Drugs and Pharmaceuticals. It derives revenue from operations in India. The company operates in a single business segment, namely Pharmaceutical Business. Its Pharmaceutical business focuses on Bone and Pain, Transplantation Immunology, and Neurosciences.

Sonoma Biotherapeutics is a South San Francisco-headquartered biotech firm engineering regulatory T-cell therapies for autoimmune diseases like celiac and inflammatory bowel conditions. Its allogeneic platform uses CRISPR editing for antigen-specific Tregs, advancing candidates through preclinical stages with manufacturing in Emeryville facilities.

Letu is a drug research and development manufacturer building a precision medicine ecosystem encompassing biological drugs, intelligent manufacturing, genetic testing, and medical services in China.

Elpiscience Biopharmaceuticals is a Shanghai-headquartered clinical-stage biopharmaceutical company developing bispecific antibodies and multispecific therapeutics for immuno-oncology. Its pipeline includes ES101, a CCR8-targeting antibody in Phase I trials across China and the United States, alongside candidates targeting TIGIT, CD47, and PD-L1. Established in 2017, the company advances novel molecules addressing tumor microenvironment mechanisms to treat solid tumors. Elpiscience collaborates with international partners like Fosun Pharma and maintains research sites in Shanghai and Suzhou.

Iambic is a San Francisco-based therapeutics company employing AI to accelerate drug discovery. Its platform integrates Enchant, a multi-modal transformer for early clinical outcome prediction, and NeuralPLexer for protein-ligand structure forecasting. By embedding physics into AI models, Iambic explores vast chemical spaces to target challenging proteins, optimize therapeutic profiles, and conduct weekly design-make-test cycles through automated labs. The company raised $15 million in seed funding in 2022.

Tizona Therapeutics advances immuno-oncology therapies targeting regulatory T cells to overcome tumor immunosuppression. Collaborating closely with its scientific founders, the company investigates Treg roles across various cancer types to inform precision treatments. South San Francisco-headquartered, Tizona differentiates through data-driven insights into tumor microenvironments.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Alkaloid AD Skopje is engaged in producing and selling pharmaceutical, chemical and cosmetic products, as well as goods from the herbal origin. Its segments are Pharmaceuticals, Chemicals, Cosmetics and Botanicals. It derives maximum revenue from Pharmaceuticals products segment.

AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.

Middle East Pharmaceutical Industries Co is a holding company is engaged in manufacturing medicines, medicated and non-medicated creams and gels. The company operates in Private, Public, and Export segments.

Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company’s focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.

Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.

Ring Therapeutics is a biotechnology company developing Anellovector gene therapies derived from human commensal viruses for redosable and targeted treatments. Backed by Flagship Pioneering and based in Cambridge, Massachusetts, it advances platforms beyond traditional gene replacement for diseases like liver disorders and muscle wasting. Founded in 2022, Ring Therapeutics pioneers viral vectors for immunology and oncology applications.

TTY Biopharm Co Ltd is engaged in the manufacturing and marketing of pharmaceuticals and chemical drugs. The company's operating segments includes Oncology Business unit, Health Care Business unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business unit segment. It generates maximum revenue from the Oncology segment. Geographically, it derives a majority of revenue from Taiwan and also has a presence in European and Other Countries. Some of its products include Algitab, Alginos, Sulfin, Metacin, Cepiro, Brosym, Colimycin, Cubicin, and others.